Daphne Zohar recently left her position as CEO of PureTech Health for a new neuroscience startup, for which she’s raised $325 million this year alone. That’s big, and her influence on the biotech field extends beyond that. She’s worked in drug development for more than two decades — starting companies, selling them, and launching them on stock markets. Last year, Zohar’s last company, Karuna, was bought by Bristol Myers Squibb. Its drug is the first new class of antipsychotic in decades and is undergoing a successful product launch. Her new firm, Seaport Therapeutics, has raised $330 million to develop new brain medicines.
From STAT:
Seaport Therapeutics adds another $225 million to coffers to embrace the ‘golden age of neuroscience”
Biotech analyst Brian Skorney and CEO Daphne Zohar weigh in on election results
Industry
Location
-
Boston, Mass.
